European countries are preparing to continue to provide medical institutions with the Johnson & Johnson vaccine against covida-19 on Wednesday, after European regulators assessed that the overall health benefits of the vaccine outweighed the risks.
The German Ministry of Health announced that it will soon begin to provide vaccines to the Johnson & Johnson vaccination centers in the federal states, and then to family medicine doctors.
To this day, the vaccine produced by this American manufacturer is still used in the Netherlands, and Italy has also decided to take this action, recommending its use in people over 60.
The Danish health authorities should announce their decision on the fate of Johnson & Johnson’s vaccine next week after further investigating its possible connection with the rare form of blood clotting.
The European Medicines Agency (EMA) said on Tuesday that its safety committee has determined that there may be a link between the American company’s vaccine and the rare blood clot formation in adults receiving the vaccine in the United States, but he emphasized that vaccination The benefits of a single vaccine outweigh the risks.
EMA found that all blood clot cases occurred in adults under the age of 60 within three weeks after vaccination, and most of them were women.
The agency clarified that all available evidence, including eight reports of blood clots in the United States, was part of its assessment.
In almost all cases, there is cerebral venous sinus thrombosis (CVST) and thrombocytopenia (platelet deficiency-platelets).
However, even though EMA believes the vaccine is safe, it has decided to leave it to alliance members to decide how to use it, just like the AstraZeneca vaccine.